FIELD: medicine.
SUBSTANCE: liquid pharmaceutical composition for peroral introduction contains pregabalin, at least, one preservative, at least, one substance masking taste, at necessity, a viscosity regulator. The composition has pH in a range from 5.5 to 7.0 and as preservative contains methyl paraben and ethyl paraben. Concentration of methyl paraben makes, at least, 2 mg/ml, and concentration of ethyl paraben - at least, 0.5 mg/ml.
EFFECT: invention provides obtaining of stable pharmaceutical composition of pregabalin with low level of chemical and microbiological impurity.
11 cl, 2 tbl, 9 ex
| Title | Year | Author | Number |
|---|---|---|---|
| PER ORAL PHARMACEUTICAL TELBIVUDIN-CONTAINING SOLUTIONS | 2008 |
|
RU2493826C2 |
| COMPOSITIONS OF PREGABALIN AND THEIR USE | 2020 |
|
RU2810596C2 |
| LIQUID PHARMACEUTICAL COMPOSITION OF GABAPENTIN (OPTIONS) | 2022 |
|
RU2792628C1 |
| LIQUID COMPOSITIONS CONTAINING VALSARTAN | 2008 |
|
RU2488393C2 |
| THE COMPOSITION OF FENFLURAMINE, COMPATIBLE WITH A KETOGENIC DIET | 2018 |
|
RU2778848C2 |
| AQUEOUS RISPERIDONE COMPOSITIONS | 1995 |
|
RU2161965C2 |
| LIQUID PHARMACEUTICAL COMPOSITION (VERSIONS) AND METHOD FOR PHOSPHOR BINDING IN GASTROINTESTINAL TRACT | 2007 |
|
RU2463060C2 |
| LIQUID ANTIACID COMPOSITIONS | 1998 |
|
RU2193889C2 |
| PHARMACEUTICAL COMPOSITION CONTAINING 5-METHYL-2-(2′-CHLORO-6′- FLUOROANILINE)PHENYLACETIC ACID | 2004 |
|
RU2363462C2 |
| PHARMACEUTICAL COMPOSITION OF SILDENAFIL CITRATE IN FORM OF SUSPENSION FOR ORAL ADMINISTRATION | 2016 |
|
RU2649834C1 |
